Marker Therapeutics, Inc.
Moat Score — Marker Therapeutics, Inc.
Total Moat Score
7 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Marker holds an exclusive worldwide license from Baylor College of Medicine to its multi-antigen MAR-T platform, backed by years of academic clinical data in lymphoma, pancreatic cancer, and post-transplant AML/MDS that a competitor cannot simply replicate. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | The off-the-shelf MT-401-OTS approach, where one donor's cells could treat ~40 patients, could eventually lower manufacturing cost versus bespoke autologous therapies, but this remains unproven in early Phase 1 trials. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With no approved products, Marker has no current pricing power; any future pricing would depend on payer negotiations typical of novel cell therapies. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Cell therapy development and treatment exhibit no network effect between patients or providers. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Once a patient begins a cell-therapy regimen there is inherent continuity, but with no approved product yet, there are no real switching costs to speak of for payers or physicians. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The CAR-T-relapsed lymphoma niche Marker targets is narrow enough, and clinically demanding enough to enter, that it faces less direct competition than mainstream CAR-T indications, though large, well-funded rivals could still enter if the data proves compelling. |